Results 111 to 120 of about 81,306 (284)

A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial

, 2015
Yoichiro Yoshida,1 Keiji Hirata,2 Hiroshi Matsuoka,3 Shigeyoshi Iwamoto,4 Masahito Kotaka,5 Hideto Fujita,6 Naoya Aisu,1 Seiichiro Hoshino,1 Takeo Kosaka,6 Kotaro Maeda,3 Fumiaki Kiyomi,7 Yuichi Yamashita1 1Department of Gastroenterological Surgery ...
Hirata K, Aisu N, Hoshino S, Kotaka M, Yamashita Y, Matsuoka H, Kiyomi F, Fujita H, Yoshida Y, Iwamoto S, Maeda K, Kosaka T   +11 more
core  

Unraveling the Multimodal Oncogenic Network of KITENIN: From Metabolic Reprogramming and Microenvironment Remodeling to Targeted Interventions

Cancer Nexus, EarlyView.
ABSTRACT KAI1 C‐terminal interacting tetraspanin (KITENIN) is an emerging oncogenic regulator associated with tumorigenesis, metastasis, therapeutic resistance, and poor clinical outcomes. Mechanistically, KITENIN promotes tumor cell proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) by activating oncogenic pathways ...
Niaz Mahmood Tanoy, Zarin Tasnim, Md Shiblee Sadik Sabuj, Tanvir Ahmed, Md Abdul Momin, Md Sadekuzzaman, Sumaia Islam Mow, Md Aktaruzzaman, Md Rashedunnabi Akanda   +8 more
wiley   +1 more source

Identification of a signature gene set for oxaliplatin sensitivity prediction in colorectal cancer

Frontiers in Oncology
BackgroundColorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Oxaliplatin-based chemotherapy is a cornerstone of treatment for many CRC patients; however, the development of chemoresistance severely limits its therapeutic ...
Xiaopeng Zhan, Xinyue Li, Yimin Chu, Ying Xu, Fengli Zhou, Ji Li, Daming Yang, Changping Hu, Haixia Peng, Zhaoxia Wu   +9 more
doaj   +1 more source

Adsorption of Oxaliplatin by Hydroxyapatite [PDF]

Bioautomation, 2007
Hydroxyapatite (HAP) is the main inorganic component of human skeleton. The last years a lot of interest is focused on its use as drug carrier. In this work the in vitro adsorption of the anti-cancer drug oxaliplatin, by HAP, from its aqueous solution ...
Papageorgiou A., Sikalidis C., Betsiou M.   +2 more
doaj  

Oxaliplatin in Cisplatin-Resistant Cancer

, 2007
Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with ...
STORDAL, BRITTA KRISTINA
core  

Predictors of Receipt oxaliplatin.

, 2018
Predictors of Receipt oxaliplatin.
Carlos R. Torres-Cintrón (5018654), Priscilla Magno (5018651), Karen J. Ortiz-Ortiz (559636), Guillermo Tortolero-Luna (5018660), Robert Hunter-Mellado (5018666), Tonatiuh Suárez-Ramos (5018657), Ruth Ríos-Motta (5018663), Alejandro Veintidós-Feliú (5018648)   +7 more
core   +1 more source

Wnt/β-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer

Journal of Translational Medicine
Background Oxaliplatin resistance usually leads to therapeutic failure and poor prognosis in colorectal cancer (CRC), while the underlying mechanisms are not yet fully understood.
Yuting Huang, Szehoi Chan, Shuna Chen, Xueqi Liu, Miao Li, Liyuan Zheng, Zhaoxia Dong, Ziyi Yang, Zixuan Liu, Disheng Zhou, Xingding Zhang, Bo Zhang   +11 more
doaj   +1 more source

Oxaliplatin-related thrombocytopenia

, 2012
Oxaliplatin is a third generation platinum compound that inhibits DNA synthesis, mainly through intrastrandal cross-links in DNA. Most of the experience with the clinical use of this drug is derived from colorectal cancer but it is also used in other ...
Rocha, V. G., Hoff, P. M., Rodrigues, C. A. [UNIFESP], Novis, Y. A. S., Jardim, D. L.   +4 more
core   +1 more source

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer

International Journal of Cancer, EarlyView.
What's New? This study introduces a novel approach for detecting locally advanced esophageal carcinoma using cell‐free DNA (cfDNA) analysis through a highly sensitive fragmentome assay. Unlike traditional sequencing‐based methods that are limited by the absence of specific mutations in esophageal tumors, our method offers an alternative by quantifying ...
Anouchka Modesto, Sophie Gibert, Caroline Delmas, David Tougeron, Amaury Paumier, Alexandre Taillez, Samuel Le Sourd, Delphine Argo Leignel, Philippe Ronchin, Ariane Darut Jouve, Véronique Vendrely, Olivier Riou, Jérôme Martin‐Babau, Thomas Leroy, Laurent Quéro, Naïma Hanoun, Pierre Cordelier, Veronica Pezzella, Jean Pierre Delord, Rosine Guimbaud, Elizabeth Moyal, Catherine Seva   +21 more
wiley   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source